
    
      This is a single-center, randomized, crossover, double-blind, placebo-controlled study
      designed to evaluate the effects of olorinab on gastric, small-bowel, and colonic transit in
      IBS participants with predominant constipation (IBS-C) or with predominant diarrhea (IBS-D).
    
  